ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2023
Biologics in eosinophilic gastrointestinal diseases.
Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Biologics for eosinophilic oesophagitis: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- BRAZILIAN GASTROENTEROLOGY FEDERATION (FBG) CLINICAL GUIDELINE: DIAGNOSIS AND TREATMENT OF EOSINOPHILIC ESOPHAGITIS IN ADULTS AND ADOLESCENTS.Arquivos de gastroenterologia · 2025Guideline
- Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders.Biomolecules · 2023Pooled it
- Advancing the understanding of eosinophilic esophagitis: From pathogenesis to novel therapies.World journal of gastrointestinal pathophysiology · 2026Review
- Article
- Nephropathic cystinosis: fibrosing colonopathy can also be seen long after introduction of delayed release cysteamine.Pediatric nephrology (Berlin, Germany) · 2026Article
- Blind-Ending Esophageal Fistula Complicating Eosinophilic Esophagitis: Case Report and Up-to-Date Strategy from Diagnosis to Therapy.Diagnostics (Basel, Switzerland) · 2026Article
- Omalizumab-Induced Remission and Steroid Withdrawal in Refractory Eosinophilic Gastroenteritis with Severe Hypereosinophilia: A Case Report.Clinical and experimental gastroenterology · 2026Article
- Eosinophilic Gastroenteritis with Atopic Dermatitis: A Case Report and Literature Review.Journal of asthma and allergy · 2026Article
- Eosinophilic gastroduodenitis: a pediatric perspective.Italian journal of pediatrics · 2025Review
- Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review.Pharmaceutics · 2025Review
- New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Practice patterns for eosinophilic esophagitis vary widely among Canadian gastroenterologists: a nationwide survey.Journal of the Canadian Association of Gastroenterology · 2025Article
- Advances in omics data for eosinophilic esophagitis: moving towards multi-omics analyses.Journal of gastroenterology · 2024Review
- Article
- The Unusual Clinical Presentation of Eosinophilic Gastroenteritis and Its Response to Mepolizumab: Two Case Reports.Cureus · 2024Article
- Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.The Journal of clinical investigation · 2024Observational
- Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.Journal of leukocyte biology · 2024Review
- A Case Report of Post-COVID-19 Eosinophilic Enteritis: An Uncommon Diagnosis in an Adult.Cureus · 2024Article
- Common and disparate clinical presentations and mechanisms in different eosinophilic gastrointestinal diseases.The Journal of allergy and clinical immunology · 2024Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Eosinophilic gastrointestinal diseases are a constellation of conditions categorized by the location of eosinophilic infiltration in the gastrointestinal tract. Symptoms vary based on location of eosinophils and age of the patient. There are no approved medications at the current time with individuals using off-label steroids or dietary therapy. Translational research has identified potential pathways to target in the treatment of eosinophilic esophagitis (EoE), gastritis (EoG), and enteritis (EoN), including type 2 pathways, mast cells, and eosinophils. Preliminary studies found cendakimab (anti-interleukin [IL]-13) and dupilumab (anti-IL-4 receptor alpha) to have an effect on eosinophil count and symptoms with dupilumab recently approved. In addition, mepolizumab (anti-IL-5), reslizumab (anti-IL-5), and lirentelimab (anti-Siglec 8) were found to have reduction in eosinophils without reduction of symptoms. For EoG and EoN, both benralizumab (anti-IL-5 receptor) and lirentelimab were found to have histologic and symptom improvement. There are no agents studied for eosinophilic colitis. Results of ongoing phase 3 trials in EoE and EoG/EoN are also anticipated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.